IPP Bureau
LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer
By IPP Bureau - December 23, 2025
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
By IPP Bureau - December 23, 2025
Full approval will depend on verification of clinical benefit in a confirmatory trial
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
By IPP Bureau - December 23, 2025
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
By IPP Bureau - December 23, 2025
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
By IPP Bureau - December 23, 2025
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
By IPP Bureau - December 23, 2025
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries
By IPP Bureau - December 23, 2025
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Cupid reduces promoter pledged stake to 20%
By IPP Bureau - December 23, 2025
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
TAKE Solutions plans AI-driven healthcare platform
By IPP Bureau - December 23, 2025
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Zydus Partners with Bioeq for US commercialisation rights for Nufymco
By IPP Bureau - December 23, 2025
NUFYMCO BLA has been approved by the USFDA
CARE Hospitals hosts insurance summit to strengthen trust in healthcare
By IPP Bureau - December 22, 2025
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Care ADHD opens its first Global Capability Centre in India
By IPP Bureau - December 22, 2025
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
By IPP Bureau - December 22, 2025
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
By IPP Bureau - December 22, 2025
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka & UBE launch joint cancer drug discovery program
By IPP Bureau - December 22, 2025
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
